You are here

Category: Most Recent

Real-time Endoscopy-Guided Measurement of Rectal Mucosal Admittance Is a Novel and Safe Method for Predicting Ulcerative Colitis Relapse.

ibdwatch

Related Articles Real-time Endoscopy-Guided Measurement of Rectal Mucosal Admittance Is a Novel and Safe Method for Predicting Ulcerative Colitis Relapse. Inflamm Bowel Dis. 2018 Jun 19;: Authors: Taida T, Arai M, Fujie M, Akizue N, Ishikawa K, Ohta Y, Hamanaka S, Ishigami H, Okimoto K, Saito K, Maruoka D, Matsumura T, Nakagawa T, Katsuno T, Kato N Abstract Background: There are known associations between inflammatory bowel disease (IBD) and changes in mucosal paracellular permeability. We recently developed a novel catheter that can measure mucosal admittance (MA). Methods: Patients with ulcerative…

Read More

Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress.

ibdwatch

Related Articles Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress. J Gastroenterol Hepatol. 2018 Jun 22;: Authors: Kim DH, Kim S, Lee JH, Kim JH, Che X, Ma HW, Seo DH, Kim TI, Kim WH, Kim SW, Cheon JH Abstract BACKGROUND AND AIM: Nuclear factor kappa B (NF-κB) activation and endoplasmic reticulum (ER) stress signaling play significant roles in the pathogenesis of inflammatory bowel disease (IBD). Thus, we evaluated whether new therapeutic probiotics have anti-colitic effects and we investigated their mechanisms related to NF-κB and ER-stress pathways. METHODS:…

Read More

Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication.

ibdwatch

Related Articles Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication. Inflamm Bowel Dis. 2018 Jun 20;: Authors: Viada Bris JF, Velasco Rodríguez-Belvís M, de Lucas Collantes C, Aparicio López C, Martínez de Azagra A, de Lama Caro-Patón G, de Prada Vicente I, Muñoz Codoceo RA Abstract Hemolytic-uremic syndrome (HUS) is defined as the triad of nonimmune hemolytic anemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). The atypical HUS (aHUS) can be considered a subtype of…

Read More

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.

ibdwatch

Related Articles Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018 Jun 21;24(23):2457-2467 Authors: Scribano ML Abstract The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action that acts on different inflammatory pathways involved in IBD pathogenesis is appealing. Vedolizumab is a fully humanised monoclonal antibody that selectively targets α4β7 integrin. Based on…

Read More

Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn’s & Colitis Foundation: Charting the Future of Pediatric IBD.

ibdwatch

Related Articles Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn’s & Colitis Foundation: Charting the Future of Pediatric IBD. Inflamm Bowel Dis. 2018 Jun 19;: Authors: Picoraro JA, Lee D, Heller CA, Weaver A, Hyams JS, Conklin LS, Otley A, Ziring D, Kugathasan S, Rosh JR, Mulberg A, Denson LA, Kappelman MD, Grossman AB, Bousvaros A, Park KT Abstract 10.1093/ibd/izy205_video1izy205.video15799266615001. PMID: 29931102 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29931102?dopt=Abstract

Read More

Uric Acid Metabolism Was Altered In Isolated Colonic Crohn’s Disease But Not Ulcerative Colitis.

ibdwatch

Uric Acid Metabolism Was Altered In Isolated Colonic Crohn’s Disease But Not Ulcerative Colitis. J Gastroenterol Hepatol. 2018 Jun 21;: Authors: Zhu F, Feng D, Zhang T, Gu L, Zhu W, Guo Z, Li Y, Lu N, Gong J, Li N Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) have higher incidence of developing nephrolithiasis. Increased uric acid production induced by Saccharomyces cerevisiae exacerbates colitis in mice. We aimed to evaluate the association between serum uric acid level and disease activity in IBD population. METHODS: Four hundred and thirty-five patients…

Read More

No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

ibdwatch

Related Articles No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Jun 21;: Authors: Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ Abstract OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and…

Read More

Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD.

ibdwatch

Related Articles Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol. 2018 Jun 21;: Authors: Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN Abstract OBJECTIVES: Immunomodulator (IM)-based monotherapy with thiopurines or methotrexate is being increasingly supplanted in the management of moderate-to-severe IBD by more efficacious biologic agents. However, given their low cost, IMs may still have a selective role in this setting. METHODS: We used a Canadian population-based dataset of persons with IBD spanning from 1996 until…

Read More

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.

ibdwatch

Related Articles NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018 Jun 19;: Authors: Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T, Onodera K, Shinozaki M, Ishiguro Y, Mizuno S, Takahara M, Yanai S, Hokari R, Nakagawa T, Araki H, Motoya S, Naito T, Moroi R, Shiga H, Endo K, Kobayashi T, Naganuma M, Hiraoka S, Matsumoto T, Nakamura S,…

Read More
<< Go Back